Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

Autor: Santoro, Armando1,2 (AUTHOR) armando.santoro@cancercenter.humanitas.it, Pilar, Garrido3 (AUTHOR), Tan, Daniel S.W.4 (AUTHOR), Zugazagoitia, Jon5 (AUTHOR), Shepherd, Frances A.6 (AUTHOR), Bearz, Alessandra7 (AUTHOR), Barlesi, Fabrice8,9,10 (AUTHOR), Kim, Tae Min11 (AUTHOR), Overbeck, Tobias R.12 (AUTHOR), Felip, Enriqueta13 (AUTHOR), Cai, Can14 (AUTHOR), Simantini, Eddy14 (AUTHOR), McCulloch, Tracey15 (AUTHOR), Schaefer, Eric S.16 (AUTHOR)
Zdroj: BMC Cancer. 10/24/2024, Vol. 24 Issue 1, p1-11. 11p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje